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Glucocerebrosidasending of the genetic basis of Parkinson's disease (PD) will lead to an appreciation
of the molecular pathogenesis of disease, which in turn will highlight potential points of therapeutic
intervention. It is also hoped that such an understanding will allow identiﬁcation of individuals at risk for
disease prior to the onset of motor symptoms. A large amount of work has already been performed in the
identiﬁcation of genetic risk factors for PD and some of this work, particularly those efforts that focus on
genes implicated in monogenic forms of PD, have been successful, although hard won. A new era of gene
discovery has begun, with the application of genome wide association studies; these promise to facilitate the
identiﬁcation of common genetic risk loci for complex genetic diseases. This is the ﬁrst of several high
throughput technologies that promise to shed light on the (likely) myriad genetic factors involved in this
complex, late-onset neurodegenerative disorder.
Published by Elsevier B.V.1. IntroductionThe exact pathobiologic basis for the progressive cellular and
systemdysfunction observed in Parkinson's disease (PD) has remained
largely elusive since the recognition of this disorder as a distinct entity.
While palliative treatments exist for this disease, it is hoped that
understanding the molecular events that lead to PD will facilitate the
creation of an etiologic based therapy that will halt or reverse the
disease process. This hope is a primary motivation underlying work
aimed at understanding the genetic basis of PD and related disorders.
Monogenic forms of parkinsonism with a clear Mendelian pattern
of inheritance have been the most accessible in terms of the
identiﬁcation of genetic causes and contributors. This work has lead
to the discovery of mutations in SNCA, PARK2, PINK1, PARK6 and
LRRK2 as causes of primary parkinsonism and/or PD. These ﬁndings
have been central to much of the investigation into the molecular
underpinnings of PD. While the identiﬁcation of these loci has been
important, mutation of these genes is responsible for a relatively small
proportion of most PD cases.
In parallel towork onmonogenic PD a large amount of research has
focused on identifying genetic variability that confers risk for, rather
than causes, PD. This work aims not only to add insight into the
molecular pathogenesis of PD, but also to create a risk proﬁle for
disease in the general population. For the most part risk variant
identiﬁcation is based on the tenet of the common-disease common-
variant hypothesis. This theory operates on the premise that commons, National Institute on Aging,
.
B.V.genetic variants underlie susceptibility for common diseases such as
PD. The common-disease common-variant hypothesis is an idea that
is the basis for the vast majority of genetic case control association
studies and the impetus for initiatives such as the International
Human Haplotype Map Project (www.hapmap.org). There has been
signiﬁcant contention over the common disease common variant
hypothesis with substantive support for the idea that rare mutations
underlie the etiology of complex disorders. While these are often
proposed as opposing theories they are not mutually exclusive;
however, the current accessible technologies do not readily allow the
investigation of rare mutations as a cause of common disease in a
complete way.
In this review we will discuss the genetic risk loci discovered thus
far in PD; we will limit our discussion to those loci for which a genetic
variant or variants have been proposed, rather than extant loci for
which no ‘gene’ has been identiﬁed. We will extend our discussion to
include a brief consideration of genomewide association studies in PD.
In general within the ﬁeld of disease genetics the search for
common genetic risk variants has been a difﬁcult and mostly fruitless
one. There are of course several reasons for this failure, particularly in
a disease such as PD. Most prominent is the size of effect and thus the
number of samples required to detect an effect. Many studies were
predicated on the idea that risk variants with effect sizes comparable
to APO E ɛ4 in Alzheimer's disease may exist for PD; thus these
generally only included sample sizes in the low hundreds. Early
genome wide association data shows quite convincingly that in terms
of common genetic risk factors, there are none with an odds ratio
greater than two in the North American White population. It is likely
that sample sizes of more than a thousand are required to detect
effects of this size. The second limitation of such studies is that
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one gene and one or a few variants, the prior odds of selecting the
correct gene and the correct variant to type were very small (i.e. there
are 10 genes that exert a measurable risk in PD and 20 SNPs, the odds
are against an investigator choosing the correct gene, out of 25,000 in
the genome or the correct SNPs, out of 2 million in the genome).
Thus the majority of previous studies were not only unlikely to
have selected a genuine risk locus or variant for interrogation but
further were likely not powered to detect risk effects, should they
exist. The exception to this work is that which has centered on
exhaustive analysis of genes already implicated in familial forms of
related disorders; such analyses provide two of the most convincing
sets of genetic association data for PD, implicating the genes SNCA and
MAPT as risk loci.
1.1. SNCA (encoding α-synuclein)
Genetic variability at SNCA is arguably the most reliable associa-
tion of a common genetic risk locus with PD identiﬁed to date. The
impetus for examination of this locus resulted from the cloning of
SNCA mutations as a cause of a rare familial form of PD. Closely
after the initial identiﬁcation of the ﬁrst disease cause mutation in
SNCA the protein product of this gene, α-synuclein, was shown to
be a major constitutive part of the pathologic hallmark inclusion of
PD, the Lewy body. The relevance of studying rare familial forms of
PD to understanding the common non-familial form of this disease
had remained in question, however these two ﬁndings elegantly
linked these disease entities; this work simply that the mutant form
of α-synuclein causes a familial form of PD and that the α-synuclein
protein is a component of the pathology of all cases of PD. Shortly
after this work Krüger and colleagues reported an association
between common genetic variability in SNCA and risk for PD,
speciﬁcally an association with an imperfect dinucleotide repeat
approximately 10 kb 5′ to the translation start site of SNCA [1].
Variability at and proximal to REP has been examined in a large
number of studies [2–9] and most recently a meta-analysis of
published studies and combination with novel data revealed a
consistent association between risk for disease and the longer REP
allele [10]. Experimental in vitro evidence suggests that this allele is
associated with increased expression of SNCA. From an etiologic
perspective this observation ﬁts well with the discovery that
multiplication of the SNCA locus, which leads to increased levels of
the wild type α-synuclein, causes familial PD [11,12]. Further the
multiplication mutations, which are to date both triplication and
duplication events appear to have a dose dependent effect on disease
severity; thus triplications that double the genomic copy number of
SNCA result in disease with an onset in the 4th decade of life and
duplications, which increase SNCA load by 50% result in disease onset
in the 5th or 6th decade of life. Given this ﬁnding it is quite
reasonable to suppose that common genetic variability at SNCA,
which may increase expression by a small amount, is a risk factor for
the late onset sporadic form of the disease. In addition to the work
characterizing the role of the REP alleles in risk for PD, more
complete analyses have shown an association between genetic
variability at other parts of SNCA with risk for disease; in particular
variability in the 3′ half of the gene [13–15]. Although this work does
not resolve the issue of which are the pathobiologically relevant
variants, they do suggests that investigation of REP alleles alone may
miss, or underestimate, the contribution of genetic variability at SNCA
to sporadic PD.
1.2. MAPT (encoding microtubule associated protein tau)
There are six major brain isoforms of the microtubule associated
protein tau (hereafter called tau) generated by alternate splicing of
exons 2, 3 and 10 of the gene MAPT. Alternate splicing of exon 10results in tau with 3 or 4microtubule binding respeats (3 repeat tau or
4 repeat tau). Tau is a major protein component of neuroﬁbrillary
tangles, a hallmark lesion of Alzheimer's disease; in these lesions tau
appears to be deposited as a hyperphosphorylated insoluble ﬁlaments.
Tau deposition is a hallmark of several other neurodegenerative
disorders, including Picks disease (OMIM#257220), argyrophilic grain
disease (OMIM#172700), corticobasal degeneration, progressive supra-
nuclear palsy (PSP; OMIM#601104) and frontotemporal dementia
(OMIM#600274).
An initial link between the MAPT locus and disease was ﬁrst
reported in 1997 by Conrad and colleagues [16]; who showed an
association between a repeat polymorphism close to the gene and PSP,
indicating that variability at this locus is a risk factor for this disorder.
In 1998 deﬁnitive evidence linking MAPT to neurodegenerative
disease was provided when Hutton and colleagues [17] identiﬁed
mutations in this gene as a cause of frontotemporal dementia with
parkinsonism linked to chromosome 17 (FTDP17). To date more than
35 mutations have been identiﬁed at the MAPT locus associated with
this disease (for a good review see [18]). Many of these mutations are
predicted to alter the alternative splicing ofMAPT, altering the ratio of
3 repeat tau to 4 repeat tau [17,19].
In addition to rare causal mutations, common variability in MAPT
has been linked to disease; notably robust association between MAPT
and risk for PSP, AD and most recently PD has been reported. From a
genomic perspective the architecture of the MAPT locus is unusual;
the gene sits within a large block approximately 1.6 million base pairs
long that shows reduced recombination and thus high levels of
linkage disequilibrium. This appears to be a result of a common
genomic inversion in the Caucasian population; this inversion inhibits
recombination between genomic fragments that are in the opposite
orientation. This phenomenon results in two common Caucasian
haplotype groups across this locus; often termed H1 and H2.
Association between MAPT H1 sub-haplotypes and risk for PD has
been tested by many groups [20–24], and the results in general show a
consistent associationwith disease, the H1 haplotype conferring a risk
with an odds ratio of approximately 1.3 (for summary statistics see the
PD Gene database http://www.pdgene.org/meta.asp?geneID=14).
Evidence is also mounting that the MAPT risk alleles for these
disorders are associated with increased MAPT expression; either in
total or speciﬁc to four-repeat tau splice variants (i.e. those containing
exon 10) [25,26]. Most recently Tobin and colleagues [27] have shown
association between PD risk and a sub-haplotype of H1; these authors
then extended this work to show over-expression of 4 repeat tau in
the brains of PD patients.
From a pathological standpoint the relationship between tau and
PD remains enigmatic: in general the brains of PD patients do not
show abundant tau positive neuropathology; however the data
supporting genetic association between MAPT and risk for PD
continues to grow and is certainly one of the more robust ﬁndings
in the ﬁeld of risk variant neurogenetics.
1.3. GBA; Glucocerebrosidase
Glucocerebrosidase is a lysosomal enzyme that hydrolyses the
beta-glycosidic linkage of glucosylceramide, a ubiquitous sphingolipid
present in the plasma membrane of mammalian cells, originating
ceramide and glucose. The human GBA gene is located on chromo-
some 1q21 and comprises 11 exons and 10 introns spanning over 7 kb.
A 5.5 kb pseudogene, which shares over 96% homology with GBA,
is located just 16 kb downstream of the functional gene. The difference
in size between the two is due o several Alu insertions in intronic
regions of GBA. On the other hand, the lack of functionality of the
pseudogene is attributed to two exonic deletions: a 4 bp deletion in
exon 4 and a 55 bp deletion in exon 9 [28]. The pseudogene is absent in
non-primate species and it has been suggested that the duplication
event that originated the two genes, occurred about 40 million years
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present a pseudogene, but instead two functional genes, hence
potentially four copies of GBA [29].
Mutations in GBA are the cause of a recessive lysosomal storage
disorder — Gaucher disease. Patients with Gaucher present macro-
phages enlarged with deposits of glucosylceramide, suggesting that
mutations in GBA act in a loss-of-function fashion [30]. Over 200
mutations have been described in GBA, including point mutations,
deletions and recombination alleles derived from the pseudogene
sequence. It has been estimated that approximately 20% of the
pathogenic mutations in GBA are caused by recombination or gene
conversion between the two genes. Although mutations are dis-
tributed over the entire GBA coding region, pathogenic mutations
seem to cluster in the carboxyl-terminal region, which encodes the
catalytic domain [31].
Phenotypes of Gaucher and Parkinson's diseases do not overlap
signiﬁcantly, but the ﬁrst indication for a relationship between the
two, actually came from clinical descriptions. These reported patients
with Gaucher disease who developed early-onset, treatment-refrac-
tory parkinsonism [32].
The ﬁrst report of an increased frequency of mutations in GBA in
Parkinson disease patients was published in 2003 [33]. Here, the
authors screened 57 brain samples from subjects with PD and 44 brain
samples from adult subjects without a diagnosis of PD. Mutations in
GBAwere identiﬁed in 14% of the PD samples, and no mutations were
found in the control samples. The percentage found in PD patients was
of particular relevance, given that the carrier frequency for Gaucher
disease-causing alleles is estimated at 0.006.
In Aharon-Peretz et al. [34] reported a screening of 99 Ashkenazi PD
patients, 74 Ashkenazi Alzheimer's disease patients and 1543 healthy
Ashkenazi Jews for six GBA mutations, considered to be the most
common cause of Gaucher among Ashkenazi Jews. A surprising
percentage of 31% of PD patients had one or two mutant alleles, when
compared toonly6%of controlswithmutations inGBA.Also, amongthe
PDpatients, thosewhowere carriers ofGBAmutationshadsigniﬁcantly
earlier age-of-onset than those who presented no mutations.
The following year, Clark et al. [35] presented a report on 160
Ashkenazi Jewish probands with Parkinson's disease and 92 clinically
evaluated, age-matched controls of Jewish ancestry. Subjects were
screened only for the N370S mutation, which was the most frequent
variant in the previous Ashkenazi Jewish study. Seventeen probands
(10.7%) were identiﬁed when compared to 4.3% controls; however
these results did not reach statistical signiﬁcance. While this variant
was described as the most frequent among this population, one
cannot help but think that a complete gene screening may have
yielded positive results.
Sato et al. [36] performed a screening for seven of the most
common variants in GBA in a series of 88 unrelated Caucasian subjects
of Canadian origin, selected for early age of onset and/or positive
family history; additionally a group of 122 healthy controls was also
screened. Mutations were enriched in the PD group when compared
with the controls (5.6% vs 0.8%); these results just about reached
statistical signiﬁcance (p=0.048).
In a smaller series of cases and controls collected in Venezuela (33
PD samples, 31 controls), Eblan et al. [37] screened the entire coding
region of the GBA gene and described an increase in mutation
frequency among the early-onset PD samples when compared to the
controls (12% vs 3.2%).
Toft et al. [38] published a report on the screening of two variants
in GBA in individuals from Norway. This was the ﬁrst report on
northern European subjects. The authors screened 311 PD patients
and 474 healthy controls for the two common mutations N370S and
L444P. They did not ﬁnd an increased frequency of mutations in PD
samples when compared to controls, however, the frequency of the
mutations was surprisingly high when compared to estimates in
white individuals (1.7% vs 0.6%). Though no statistical signiﬁcancewasobtained, the fact that only two variantswere screened in a population
not previously studied, may account for the lack of association.
Several other studies reported positive associations of GBA
mutations with PD, and one with Lewy bodies disorders. The most
recent studies, which performed complete screenings of the gene, all
found an association with PD in their study populations. Clark et al.
[39] performed a study with two subsets of PD patients: one with
Jewish ancestry and another without Jewish background. Controls
were also selected to match each of these groups. The frequency of
GBA mutations is always greater in PD samples when compared to
controls, particularly if only early-onset PD samples are considered.
Our group recently published a report on a cohort of Portuguese
samples, where the enrichment of mutations among PD samples is
also clear. This is the ﬁrst report to obtain a clear statistically
signiﬁcant association in a population other than Ashkenazi Jewish.
However, this same population has been shown to present an
increased frequency of the G2019S mutation in the gene LRRK2;
which is a Jewish mutation [40].
An interesting result regarding GBA, and lysosomal enzymes in
general, comes from the report of Balducci et al. [41] who tested PD
patients and controls for activity of lysosomal hydrolases in the CSF.
GBA activity was signiﬁcantly reduced in the CSF of PD patients, as
would be expected by a loss-of-function model of mutations in these
samples.
Given all these results it seems clear that mutations in GBA are a
risk factor for the development of PD, particularly early-onset PD. The
mechanism by which mutations exert their effect and act as a risk
factor is not yet understood, but several tentative explanations have
been provided in the literature, relating to decrease in lysosomal
function or involvement of the ubiquitin proteasome system.
1.4. Lrrk2
Mutations in LRRK2 were identiﬁed as a cause of PD in 2004 by us
and others [42–43]. A single mutation, G2019S, is a relatively common
cause of PD in Caucasian populations, underlying approximately 2% of
sporadic PD cases in North America and Northern Europe and 5% of
cases with a positive family history for disease [44–46]. This mutation
is more common in populations such as those from Portugal, those of
Ashkenazi Jewish origin and from North African Arab populations;
with this mutation underlying 8%, 21% and 41% of disease in these
populations respectively [47–49]. The G2019S does not however occur
at appreciable frequency in control cohorts from these populations, so
for the purpose of this article we will not designate this as a
susceptibility variant. Two variants reported from Asian populations
however, do appear to be true risk variants for PD. The ﬁrst G2385R
was initially described in a Taiwanese family ([50]; neurogenetics).
Assessment of this variant in large Asian populations showed
association with risk for disease in Taiwanese [51–53], Japanese [54],
Hong Kong Chinese [55] andmainland Chinese [56,57] populations. In
general this work showed that the risk variant, 2385R is present in PD
populations at a frequencyof∼10%,whereas it is only found in 0.5%–5%
of controls. Taking a fairly conservative view of these results would
suggest that carrying the risk allele imparts a two-fold risk increase in
the chance of Parkinson's disease. Given that this association appears
robust across Asian populations, this risk allele is an underlying factor
in a very large number of PD cases worldwide.
More recently a second LRRK2 risk allele, also identiﬁed within
Asian PD populations has been described [58,59].
1.5. OMI/HTRA2
Variants in the gene OMI/HTRA2 (OMIM #606441) were recently
associated with an increased risk for PD [60]. This gene encodes a
serine-protease with proapoptotic activity containing a mitochondrial
targeting sequence at its N-terminal region. Several lines of evidence
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the ﬁrst of which was produced by Gray and colleagues [61] when
they showed that Omi/HtrA2 interacts with presenilin-1, which is
encoded by a gene known to be involved in Alzheimer's disease.
Moreover beta-amyloid, which plays a pivotal role in the pathogenesis
of Alzheimer's, was shown to be cleaved by Omi/HtrA2 [62]. Mouse
models also provided support for the involvement of this protein in
neurodegeneration; a mutation in the protease domain of Omi/HtrA2
was found as the genetic cause underlying the disease in the mnd2
mutant mouse [63] and the knockout mouse showed loss of neurons
in the striatum concomitant with parkinsonian features [64].
The description of mutations associated with PD came from the
work of Strauss and colleagues in [60]. Here, they screened a large
cohort of 518 German PD patients and 370 healthy control individuals
for mutations in OMI/HTRA2. One variant (p.G399S) was found only in
PD patients (n=4) suggesting that it would be a pathogenicmutation.
The other variant (p.A141S) was found signiﬁcantly overrepresented
in the PD group (p=0.039) suggesting that it would act as a risk factor
for PD. In vitro studies of both variants provided evidences of
functional roles. Additionally, Omi/HtrA2 was detected in Lewy
bodies in brain tissue from PD patients.
More recently, Simon-Sanchez and Singleton [65] presented a
thorough analysis of the coding region of OMI/HTRA2 in a case-control
study, which comprised a large cohort of PD patients (n=644) and
neurologically normal controls (n=828). Themutation initially thought
to be pathogenic was found at the same frequency in PD samples and
controls (0.77% and 0.72% respectively), indicating that it is not disease
causing, but probably a rare variant in the Germanpopulation. Similarly
for the p.A141S variant, no association with PD was found.
Evidence for the involvement of Omi/HtrA2 in neurodegenerative
diseases are quite compelling at this point, but the genetic basis for
this involvement is still not clear.
1.6. Heterozygous mutations in genes that are recessive loci for
monogenic PD as risk factors for sporadic PD
Mutation of the gene PARK2, was the second genetic cause of
parkinsonism identiﬁed. Mutation of this gene was found to cause an
autosomal recessive juvenile form of parkinsonism. As with many
autosomal recessive diseases, most pathogenic mutations are loss ofTable 1
Replicated studies of risk variants in Parkinson's disease
Gene Variant Population MAF
SNCA
REP-1 Caucasian 0.07
REP-1 Asian 0.33
rs11931074 Caucasian 0.09
rs1812923 Caucasian 0.45
Asian 0.70
rs2301134 Caucasian 0.50
rs2583988 Caucasian 0.30
rs2619363 Caucasian 0.30
Asian 0.01
rs2619364 Caucasian 0.30
rs2737029 Caucasian 0.45
Asian 0.68
rs356165 Caucasian 0.44
Asian 0.33
rs356219 Caucasian 0.42
rs356221 Caucasian 0.49
MAPT rs242557 Caucasian 0.40
Asian 0.65
rs242562 Caucasian 0.38
Asian 0.43
rs3785883 Caucasian 0.19
Asian 0.16
GBA N370S (A1226G) Caucasian 0.03
Data downloaded fromwww.pdgene.com including all studies replicated in at least four indep
(PAR%) were calculated for each variant.function variants, involving large structural genomic disruption of the
coding region of the gene or premature termination of the transcript;
in addition several missense mutations have been identiﬁed with
varying levels of proof vis a vis association with disease. More
controversial still, is the role of single heterozygous mutations as risk
factors for late onset typical PD. Much of this work has been driven by
observations in family based studies where later onset typical PD was
seen in relatives of patients with young onset parkinsonism— analysis
of these cases revealed homozygous or compound heterozygous
PARK2 mutations in the young-onset cases and possession of single
PARK2 mutations in the later onset affected relatives; such studies
have been criticized because of the signiﬁcant confound of ascertain-
ment bias; i.e. the families that tend to be collected and analyzed are
those with many affected family members. Further support for the
role of single PARK2 mutations as a risk factor for disease is the
observation that heterozygous mutation carriers display dopamine
reuptake deﬁciency in fdopa PETanalysis [66]. The strength of the case
for a role of heterozygous PARK2mutations as risk loci based on these
observations, and on data arising from case control analyses
examining this issue, has been hindered by the lack of studies that
have performed full sequence and gene dosage analysis of PARK2 in
large groups of cases and controls. Only a small number have studies
have taken this approach and so far that data does not strongly
support a large role for these mutations in typical PD, identifying
pathogenic mutations in the heterozygous state in both cases and
controls. This issue warrants a large scale sequencing effort, however,
it is likely that several thousand cases and controls will need to be fully
sequenced to ﬁnally prove or disprove this putative association.
1.7. Genome wide association studies
Genome wide association studies (GWAS) were a much-antici-
pated technology, and the application of this approach is expected to
make major inroads into our understanding of the genetic basis of
disease [67]. The basic tenet underlying GWAS is the common disease
common variant hypothesis. A growing number of GWAS are being
published and these are proving a valuable approach in understanding
the genetics of complex disease. Two studies have been published
thus far in PD; the success of these studies was limited somewhat by
the sample size used, a point that is illustrated by the failure of theseaffected MAF unaffected OR PAR%
0.06 1.2 0.71
0.29 1.2 3.07
0.07 1.3 1.04
0.44 1.04 1.16
0.69 1.01 0.70
0.49 1.02 0.58
0.27 1.17 2.45
0.28 1.13 1.47
0.00 1.09 0.02
0.27 1.16 2.42
0.39 1.31 6.42
0.58 1.59 15.16
0.36 1.42 7.58
0.43 1.51 13.14
0.36 1.28 6.28
0.48 1.02 0.61
0.38 1.11 2.13
0.60 1.23 8.76
0.37 1.01 0.28
0.38 1.20 3.76
0.18 1.00 0.08
0.14 1.15 1.50
0.02 1.32 0.52
endent case–control samples. Odds ratios (ORS) and population attributable risk factors
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the increasing investment in this technology [68] it is probable that
several laboratories around the world are investing in large-scale
GWAS in PD and that the next 2 years will see the identiﬁcation of
novel risk loci for this disease.
Because GWAS require large sample series they necessitate inter-
laboratory collaborations and large consortia, individual investigators
are by and large, unable to accumulate large enough series. Clearly the
formation of such collaborations is a good thing for research; they
facilitate communication between scientists, maximize the chances of
ﬁnding positive signals and engender trust between research groups
that allows collaboration outside the immediate aims of the
collaborative framework. This latter point is particularly critical; as
technologies improve GWAS will be expanded to include better
genomic coverage (currently even the most dense SNP platforms
probably only capture ∼70% of common variation) in more samples.
The most immediate challenge following GWAS will be in under-
standing the pathobiological consequences of identiﬁed risk variants.
These will not easily be amenable to traditional disease model
approaches used now in cell biological and transgenic research; the
primary limitation being that the biological effects of risk variants are
likely extremely subtle. Parsimony would suggest that the majority of
identiﬁed risk variants will be non-coding, in all likelihood exerting an
effect through expression, either modulating constitutive levels,
expression level in response to a stimulus, sub-cellular expression
and/or splicing. The easiest of these to catalog are alterations in
expression and indeed some effort has gone toward characterizing in a
genome wide manner, the effects of individual genetic variants on
expression of proximal (cis) and distal (trans) transcripts [69]. The
creation of standard genotype-expression transcript maps will be a
critical step in understanding the effects of disease associated genetic
variants, and there have already been moves to create such a resource
(http://nihroadmap.nih.gov/GTEx/).
While GWAS are providing a unique set of insights into complex
diseases, it is only the ﬁrst of many burgeoning technologies that will
impact our understanding of biology and disease. Most anticipated of
these is cost-effective genome wide resequencing; the launch of this
type of work is a goal of the 1000 genomes project (http://
www.1000genomes.org/page.php), which aims to catalog rare and
common human variation by sequencing the genome of at least 1000
individuals from around the World. Currently this is a huge endeavor
and genome resequencing for case-control analysis is cost- and time-
prohibitive; however, this is likely to change over the next 2–5 years.
The type of next generation sequencing employed for this research
will not only facilitate genome resequencing but also allows us to
analyze other features previously impractical; this includes genome
wide assays of DNA methylation, analysis of histone modiﬁcation,
analysis and identiﬁcation of transcription binding sites, full tran-
scriptome sequencing and identiﬁcation of allelic imbalance in
expression. Each of these approaches provides revolutionizing data
in their own right; however, the true power of such data will become
evident as we integrate these datasets to garner a systems based
understanding of biological and disease processes.
In summary, there are several common risk loci unequivocally
associated with risk for PD (see Table 1) in each instance these genes
were originally implicated in the disease process by studying families
with disease. The advent and application of novel technologies
promises to deﬁne other common genetic variants that exert risk for
disease, help in the identiﬁcation of rare risk variants and facilitate in
the understanding of the pathobiological consequences of genetic
variants linked with disease.
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